Literature DB >> 34176000

Tuberculosis of the spine and drug resistance: a review article.

Vishal Kumar1, Deepak Neradi1, Balwinder Sherry1, Ankit Gaurav1, Sarvdeep Singh Dhatt2.   

Abstract

Pott's spine is tuberculosis of spine caused due to hematogenous spread of mycobacterium from a primary focus. It constitutes about 50% of skeletal tuberculosis cases. Paradiscal type is the most common type of spinal tuberculosis. Untreated cases can lead to complications like a cold abscess, paraplegia, and deformity which may require surgical intervention. Rapid molecular methods have made the diagnosis of spinal tuberculosis and drug resistance faster and easier but it still remains a problem due to difficulties in sample collection and the paucibacillary nature of the Pott spine. Antitubercular drug therapy forms the mainstay of management. The emergence of MDR TB and XDR TB has posed a big challenge in the management of spinal tuberculosis. The literature regarding drug resistance in spinal tuberculosis and its management is lacking. We conducted a literature review of 29 studies and presented information on pathogenesis, diagnosis, and management of spinal tuberculosis and drug resistance. New shorter regimens for MDR and XDR TB are under trial in different parts of the world. We believe this article will provide information on spinal tuberculosis and drug resistance and help clinicians outline important research areas.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Diagnosis; Drug resistance; Epidemiology; Management; Pathogenesis; Spinal tuberculosis

Mesh:

Substances:

Year:  2021        PMID: 34176000     DOI: 10.1007/s10143-021-01595-1

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  3 in total

1.  Spinal tuberculosis in developed countries: difficulties in diagnosis.

Authors:  A J Hayes; M Choksey; N Barnes; O C Sparrow
Journal:  J R Coll Surg Edinb       Date:  1996-06

Review 2.  Tuberculous spondylodiscitis: epidemiology, clinical features, treatment, and outcome.

Authors:  E M Trecarichi; E Di Meco; V Mazzotta; M Fantoni
Journal:  Eur Rev Med Pharmacol Sci       Date:  2012-04       Impact factor: 3.507

Review 3.  Molecular biology of drug resistance in Mycobacterium tuberculosis.

Authors:  Tasha Smith; Kerstin A Wolff; Liem Nguyen
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

  3 in total
  3 in total

1.  Clinical Features and Outcome of Multidrug-Resistant Osteoarticular Tuberculosis: A 12-Year Case Series from France.

Authors:  Isabelle Bonnet; Elie Haddad; Lorenzo Guglielmetti; Pascale Bémer; Louis Bernard; Anne Bourgoin; Rachel Brault; Gaud Catho; Eric Caumes; Lélia Escaut; Eric Fourniols; Mathilde Fréchet-Jachym; Alice Gaudart; Hélène Guillot; Barthélémy Lafon-Desmurs; Jean-Philippe Lanoix; Philippe Lanotte; Adrien Lemaignen; Bénédicte Lemaire; Nadine Lemaitre; Christophe Michau; Philippe Morand; Faiza Mougari; Dhiba Marigot-Outtandy; Solène Patrat-Delon; Thomas Perpoint; Caroline Piau; Valérie Pourcher; Virginie Zarrouk; Valérie Zeller; Nicolas Veziris; Stéphane Jauréguiberry; Alexandra Aubry
Journal:  Microorganisms       Date:  2022-06-14

2.  Comparison of Clinical Data Between Patients With Complications and Without Complications After Spinal Tuberculosis Surgery: A Propensity Score Matching Analysis.

Authors:  Liyi Chen; Chong Liu; Zhen Ye; Wuhua Chen; Xuhua Sun; Jiarui Chen; Hao Li; Tuo Liang; Shengsheng Huang; Jie Jiang; Tianyou Chen; Hao Guo; Yuanlin Yao; Shian Liao; Chaojie Yu; Shaofeng Wu; Binguang Fan; Xinli Zhan
Journal:  Front Surg       Date:  2022-03-29

3.  Blood transfusion risk prediction in spinal tuberculosis surgery: development and assessment of a novel predictive nomogram.

Authors:  Liyi Chen; Zhaoping Gan; Shengsheng Huang; Tuo Liang; Xuhua Sun; Ming Yi; Shaofeng Wu; Binguang Fan; Jiarui Chen; Tianyou Chen; Zhen Ye; Wuhua Chen; Hao Li; Jie Jiang; Hao Guo; Yuanlin Yao; Shian Liao; Chaojie Yu; Chong Liu; Xinli Zhan
Journal:  BMC Musculoskelet Disord       Date:  2022-02-25       Impact factor: 2.362

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.